Progression of a series of patients with relapsing-remitting multiple sclerosis treated for 7 years with natalizumab using the “no evidence of disease activity” parameter-Reference-Cited by-同舟云学术

Progression of a series of patients with relapsing-remitting multiple sclerosis treated for 7 years with natalizumab using the “no evidence of disease activity” parameter

Published:2020-02 Issue: Volume: Page:
ISSN:2173-5808
Container-title:Neurología (English Edition)
language:en
Short-container-title:Neurología (English Edition)

Author:

Pato Pato A.,Costa Arpín E.,Rodríguez Regal A.,Rodríguez Constenla I.,Cimas Hernando I.,Muñoz Pousa I.,Naya Ríos L.,Lorenzo González J.R.,Amigo Jorrín M.C.,Prieto González J.M.

Publisher

Elsevier BV

Subject

General Materials Science

Reference17 articles.

1. Monoclonal antibodies as disease modifying therapy in multiple sclerosis;Longbrake;Curr Neurol Neurosci Rep,2013

2. Biogen Idec. TYSABRI® (natalizumab) intravenous injec-tion monoclonal antibody. 2013. Food and Drug Admi-nistration. Reference ID: 3753128. Available from: http://www.tysabri.com/prescribingInfo.

3. Monoclonal antibody therapies for the treatment of relapsing-remitting multiple sclerosis: differentiating mechanisms and clinical outcomes;Lycke;Ther Adv Neurol Disord,2015

4. Progressive multifocal leukoencephalopathy and natalizumab;Hellwig;J Neurol,2011

5. Anti-JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy;Plavina;Ann Neurol,2014

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Drug-Induced Progressive Multifocal Leukoencephalopathy (PML): A Systematic Review and Meta-Analysis;Drug Safety;2024-02-07

2. Natalizumab;Reactions Weekly;2021-07